Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Whitehead Jr. who wrote (886)	5/27/1999 7:41:00 PM
From: Silver Knife	Read Replies (3) of 2344

Dow Jones Newswires May 27, 1999 DJ Biomira Reports Enrollment For Phase III Theratope Trial TORONTO -- Biomira Inc. (BIOM) said it has enrolled 101 patients with metastatic breast cancer in the Phase III clinical trial for its Theratope cancer vaccine. In a news release, the company said the multinational pivotal trial will involve 900 evaluable patients at about 75 sites worldwide. It said the trial is the largest immunotherapy trial of its kind ever conducted in metastatic breast cancer patients. The company said the trial will provide the opportunity to obtain statistically significant data which will be critical in the approval and marketing of the product when the trial is complete. Biomira said that, in total, Theratope vaccine has been tested in more than 350 patients in Phase I and Phase II clinical trials in the U.S., Canada and the U.K. Biomira is a biotechnology company. Briefing Book for: BIOM \| T.BRA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next